Zydus Lifesciences Completes Acquisition of Sterling Biotech API Business

Mumbai, November 02: Zydus Lifesciences Limited has completed the acquisition of the active pharmaceutical ingredient (API) business of Sterling Biotech Limited, according to a regulatory filing.

The company confirmed that the transaction was completed after fulfilling the conditions precedent and closing-date adjustments specified in the Business Transfer Agreement (BTA) executed between the two companies on September 17, 2024.

The latest update follows earlier extensions to the transaction timeline while Sterling Biotech worked to fulfil certain conditions required for completion. Zydus had initially expected the acquisition to be completed by December 31, 2024.

Acquisition of API Business

The acquisition adds Sterling Biotech’s API business to Zydus Lifesciences’ pharmaceutical operations. APIs are the active ingredients responsible for the therapeutic effect of medicines.

In its September 2024 announcement, Zydus identified the target business as having a portfolio of fermentation-based API products, including Lovastatin, Daunorubicin, Doxorubicin and Epirubicin. The original business transfer agreement carried a lump-sum consideration of ₹84 crore.

The completion announcement confirms that the acquisition has now closed. The company did not provide additional financial details in the latest intimation.

Stock Market Snapshot

The Zydus Lifesciences share price was trading at ₹1,237.60, down 0.63% on Monday, November 2, compared with the previous close of ₹1,245.50. The stock opened at ₹1,250.00.

The quote reflects the intraday price displayed at 1:11:03 PM IST. The price movement alone does not establish a direct link between the acquisition update and the stock’s performance.

About Zydus Lifesciences

Zydus Lifesciences Limited is an Indian pharmaceutical company engaged in developing, manufacturing and marketing medicines and healthcare products across domestic and international markets.

Conclusion

Zydus Lifesciences has completed its acquisition of Sterling Biotech’s API business, concluding a transaction process that began in September 2024. The deal expands the company’s portfolio of fermentation-based active pharmaceutical ingredients.

Source:

• https://www.nseindia.com/get-quote/equity/ZYDUSLIFE/Zydus-Lifesciences-Limited
• https://nsearchives.nseindia.com/corporate/Cadilahc_02112026124012_Zydus_SBL_API_BTA_closing.pdf